Inactivation of oncoprotein binding by a single Cys706-to-Tyr substitution in the retinoblastoma protein  by Saijo, Masafumi et al.
FEBS Letters 340 (1994) 181-184 LETTERS 
ELSEVIER 
FEBS 13730 
Inactivation of oncoprotein binding by a single Cys706-to-Tyr substitution 
in the retinoblastoma protein 
Masafumi Saijoa,**, Mitsuo V. Katob.***, Masao S. Sasakib, Kanji Ishizakib, Yoichi Taya”>* 
‘Biology Division, National Cancer Center Research Institute, Tsukiji. Chuo-ku, Tokyo 104, Japan 
bRadiation Biology Center, Kyoto University, Yoshida-konoecho, Sakyo-ku, Kyoto 606, Japan 
Received 6 December 1993 
Abstract 
We previously found a new single amino acid substitution at codon 706 (Cys-to-Tyr) of the retinoblastoma (RB) gene in a sporadic retinoblastoma 
patient. The glutathione S-transferase-RB fused protein containing this mutation was here tested for binding to SV40 large T antigen and adenovirus 
ElA protein, and was shown to have lost its binding affinity. Thus, Tyr, as well as Phe, residues substituted for Cys706 were found to abolish the 
RB protein activity. 
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1. Introduction 
Inactivation of both alleles of the retinoblastoma (RB) 
gene appears to trigger a wide range of human tumors 
[l]. The RB gene product (pRB) is a 110 kDa nuclear 
phosphoprotein [2]. It has been demonstrated that the 
adenovirus ElA protein [3] and the SV40 large T antigen 
[4] as well as the human papillomavirus E7 protein [5] 
form a complex with pRB, presumably resulting in inac- 
tivation of pRB function. It was also shown that pRB is 
phosphorylated cell cycle-dependently [69]. This phos- 
phorylation is likely to be performed by cyclin-depend- 
ent kinases [l&16] and appears to regulate the anti- 
proliferative activity of pRB [17]. It has been suggested 
that this activity of pRB is mediated through binding to 
several cellular proteins including E2F [17]. 
Several types of naturally occurring inactivated mu- 
tant pRB have been found in tumor cells [ 18-241. Among 
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these, a 35-amino acid deletion in exon 21 was first iden- 
tified in the bladder carcinoma cell line 582 [19] and the 
prostatic carcinoma cell line DU145 [20]. C-Terminal 
truncation lacking exons 21-27 was found in an os- 
teosarcoma cell line Saos-2 [21]. Similarly, a 25-amino 
acid deletion around exon 16 was found in the small cell 
lung carcinoma cell line SCLC-SD1 [22]. In addition, a 
single amino acid substitution (Cys to Phe) at codon 706 
which was derived from exon 21 was identified in a small 
cell lung cancer cell line H209 [23,24]. These mutant pRB 
are uniformly underphosphorylated, rendering them un- 
able to bind to the adenovirus ElA protein or SV40 large 
T antigen. It is interesting to note that all of these muta- 
tions are located within two non-contiguous regions of 
pRB, amino acid residues 394-571 and 649-773, which 
are needed for binding to ElA protein or SV40 large T 
antigen [25,26]. 
We previously found a new single amino acid substitu- 
tion at codon 706 (TGT-to-TAT: Cys-to-Tyr) of the RB 
gene in a sporadic bilateral retinoblastoma patient 
RB210 [27]. The mutation was heterozygous in the fi- 
broblast of this patient and homozygous in the tumor. 
We have now demonstrated that this mutation results in 
the inability of pRB to bind to ElA protein or SV40 large 
T antigen. 
2. Materials and methods 
2. I. Materials 
Plasmid p4.95BT which contains RB cDNA was generously provided 
by Dr. T.P. Dryja. Fibroblasts of the RB210 patient were obtained and 
cultured as described previously [28]. Purified SV40 large T antigen was 
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3. Results and discussion kindly supplied by Dr. T. Eki (RIKEN). Monoclonal antibodies against 
adenovirus ElA protein, SV40 large T antigen, and pRB were pur- 
chased from Oncogene Science. 
2.2. Construction of pGEX-3XX 
To generate in-frame glutathione S-transferase-RB fused proteins, 
we modified plasmid pGEX-3X [29]. For this purpose, pGEX-3X was 
linearized with BamHI, blunt-ended by T4 DNA polymerase, and then 
ligated. The plasmid vector thus obtained was named pGEX-3XX. 
2.3. Construction of plasm& to produce GST-RB fusion proteins 
Plasmid p4.95BT was digested with VspI and the resulting 2.0 kb 
fragment, which contains a coding region (385-928) and the 3’ non- 
coding region of the RB gene, was purified from an agarose gel. Termini 
of the fragment were blunt-ended with T4 DNA polymerase, and then 
ligated to the SmaI site of pGEX-3XX. This clone will be referred to 
as pGST-RB(385-928). 
In order to obtain the RB cDNA with a point mutation at position 
706, 10 mg of total RNA from cultured RB210 fibroblasts was reverse- 
transcribed and amolified usine GCGAATTCCAGACTGATTCTA- 
TAGACAG, which ‘is derived corn the exon 10 sequence, as the up- 
stream primer and ATGTCGACTCCAGAGGTGTACACAGTG, 
which is derived from the sequence of the 3’ non-coding region of exon 
27, as the downstream primer, according to the method of Kato et al. 
[27]. The PCR product was digested with NheI and BsmI and purified. 
A NheI-BsmI fragment of the wild-type RB cDNA was excised from 
pGST-RB(385-928) and replaced by the corresponding fragment of 
PCR product. A clone was obtained which was confirmed to have a 
mutation at codon 706 by DNA sequencing using double-stranded 
DNA as a template. This clone was designated pGST-RB(385-928; 
706Y). 
2.4. Expression and purification of GSTfusion proteins 
GST-RB fusion proteins were expressed and purified essentially as 
described by Smith and Johnson [29]. E. coli cells transformed with 
pGST-RB(385-928) or pGST-RB(385-928; 706Y) were grown to A,, 
0.5, and IPTG was added to a final concentration of 1 mM. After 3 h 
of additional growth, E. coli cells were pelleted, washed once with PBS, 
and stored at -8O’C. Cells were resuspended in l/30-1/50 culture vol- 
ume of NETN (20 mM Tris-HCl, pH 8.0,lOO mM NaCl, 1 mM EDTA, 
0.5% NP-40,0.25 mM PMSF, lOpg/ml each of antipain, chymostatin, 
leupeptin and pepstatin) and lysed on ice by sonication. Lysates were 
centrifuged at 28,000 x g for 15 min, and cleared lysates were incubated 
with glutathione-Sepharose (Pharmacia) for 30 min at 4°C. The beads 
were washed three times with NETN. Elution of the GST-RB fusion 
proteins was performed with a buffer containing 50 mM Tris-HCl, pH 
8.0, 100 mM NaCl, and 5 mM glutathione. 
2.5. Assay for binding of pRB to DNA tumor virus oncoproteins 
293 cells, which produce adenovirus ElA protein, were used for the 
source of ElA. 293 cells (3 x 106) were lysed by a lysis buffer (50 mM 
HEPES, pH 7.0, 250 mM NaCl, 0.1% NP-40, 0.25 mM PMSF, and 5 
&ml each of antipain, chymostatin, leupeptin, and pepstatin) on ice 
for 30 min, and then centrifuged at 15,000 rpm for 5 min by a microcen- 
trifuge. The resultant supematant was used for the binding assay. 
GST-RB fused proteins (500 ng) adsorbed to glutathione-Sepharose 
beads (10 ~1) were incubated with purified SV40 large T antigen (100 
ng) or 300 ,~l of whole-cell ysate of 293 cells in a final volume of 1 ml 
of lysis buffer for 2 h at 4°C and then washed six times with NETN. 
The beads were boiled in SDS samule buffer (62.5 mM Tris-HCl. PH 
6.8, 2% SDS, 10% glycerol, 0.1 M DTT, and 6.01% Bromphenol biue) 
and bound proteins were separated by 7.5% SDS-polyacrylamide gels. 
SV40 large T antigen and ElA protein were identified by immunoblot- 
ting with-the corr&ponding monoclonal antibody using the ECL West- 
ern blotting detection system (Amersham). 
To confirm the specificity of the binding, reciprocal binding experi- 
ments were also carried out. Purified T antigen (400 ng) were im- 
munoprecipitated with anti-T antigen monoclonal antibody, then the 
immunoprecipitates were mixed with GST-RB fusion proteins (500 ng) 
in a final volume of 1 ml of lysis buffer for 2 h at 4°C. The bound 
GST-RB proteins were detected as described above with anti-pRB 
monoclonal antibody. 
To test the binding affinity for ElA protein or SV40 
large T antigen, GST-RB fused proteins containing the 
EIA-binding domain (Fig. 1A) were expressed using the 
wild-type RB gene as well as the RB gene of RB210 
mutated at codon 706 (Cys-to-Tyr) as described in sec- 
tion 2. These two clones were named pGST-RB(385- 
928) and pGST-RB(385-928; 706Y), respectively. Nu- 
cleotide sequences around codon 706 of these two plas- 
mids, are shown in Fig. 1B. 
GST-RB fused proteins thus expressed were adsorbed 
to glutathione-Sepharose beads and tested for binding 
of purified SV40 large T antigen (Fig. 2A). Mutant GST- 
RB protein did not bind SV40 large T antigen (lane 5) 
while wild-type GST-RB protein clearly bound to it 
(lane 2). Binding of SV40 large T antigen to wild-type 
GST-RB protein was completely abolished by the addi- 
tion of T-peptide [30] which contains the consensus 
LXCXE sequence for binding to pRB, but not by K- 
peptide [30] which is changed at this sequence (lanes 3, 
4), indicating that binding of GST-RB protein to SV40 
large T antigen shown here is specific. GST alone did not 
show binding (lane 1). 
These GST-RB fused proteins were also tested for 
binding to adenovirus ElA proteins (Fig. 2B). Lysates 
of 293 cells which express ElA protein were used for this 
experiment. EIA protein strongly bound to wild-type 
GST-RB protein (lane 2) and this binding was strongly 
inhibited by T-peptide (lane 3) but not by K-peptide 
(lane 4). In contrast, no binding was observed in the case 
of mutant GST-RB protein (lane 5). GST alone did not 
bind ElA protein, either. In Fig. 2A and B, the amounts 
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Fig. 1. pGST-RB(3855928) and pGST-RB(385-928; 706Y). (A) Sche- 
matic representation of GST-RB proteins. The hatched regions indi- 
cate the two domains needed for ElA or SV40 large T-binding [25,26]. 
(B) Nucleotide sequences around codon 706 of the two pGST-RB 
plasmids. 
M. Sauo et al. IFEBS Letters 340 (1994) 181-184 
of wild-type and mutant GST-RB proteins used were 
almost the same, as shown in Fig. 3, lanes 5 and 6. 
Reciprocal binding experiments were carried out using 
immunoprecipitated SV40 large T antigen and purified 
soluble GST-RB proteins (Fig. 3). It is clear that wild- 
type GST-RB protein but not mutant GST-RB protein 
bound SV40 large T antigen (lane 3 and 4). 
We showed that this newly found, naturally occurring 
-T antigen 
-ElA 
Fig. 2. Prectprtatron of SV40 large T antigen or ElA protein by wild- 
type GST-RB protein. (A) GST-RB proteins (lanes 2-5) or control 
GST (lane 1) bound to glutathione-Sepharose beads were incubated 
with SV40 large T antigens in the presence or absence of T- or K- 
peptides (100 ng each). SV40 large T antigens bound to the beads were 
detected by Western blotting with antiSV40 large T antibody. In lane 
6, 100 ng of SV40 large T antigen was loaded on SDS-polyacrylamide 
gels. (B) Lanes 1-5, experiments were carried out as in (A); however, 
293 cell lysates were used in place of SV40 large T antigen and ElA 
proteins bound to the beads were detected by Western blotting with 
anti-ElA antibody. Lane 6, 10 ~1 of 293 cell lysates were loaded for 
Western blotting. 
183 
Tantigen - - + + 
GST-RB W m W m w m 
+GST-RB 
5 6 
Fig. 3. Precipitation of wild-type GST-RB protein by SV40 large T 
antigen. Lanes 14, wild (w) or mutant (m) GST-RB proteins were 
mixed with SV40 large T antigen which was immunoprecipitated by 
anti-T antigen antibody and bound GST-RB proteins were detected by 
Western blotting using anti-pRB antibody. Lanes 5 and 6,40 ng each 
of wild-type or mutant GST-RB proteins were directly loaded onto the 
SDS-polyacrylamide gels. 
single amino acid substitution at codon 706 (Cys to Tyr) 
of pRB causes the loss of binding affinity to SV40 large 
T antigen and ElA protein. The only other example of 
a single pRB amino acid substitution, which was shown 
to inactivate pRB, is the Cys to Phe mutation at codon 
706 in a small cell cancer cell line (H209). Thus, this Cys 
residue appears to be very important for the integrity of 
pRB structure and is a frequent target for mutation of 
the RB gene. Kratzke et al. [31] recently reported func- 
tional analysis at this Cys residue of the pRB. They 
constructed in vitro a series of missense mutants at this 
codon and found substitution to Tyr as well as Phe 
caused the affinity to bind SV40 large T antigen or El A 
protein to be lost. This result is consistent with our re- 
sults which were obtained from the naturally occurring 
mutant RB gene. Moreover, they found that substitution 
of Cys-to-Ala or -Ser retained this binding affinity. Thus, 
this Cys706 residue is not involved in disulfide pairing and 
a large R-group chain at this position disrupts, by steric 
hindrance, an important pRB folding conformation. 
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